A few weeks after the United States Supreme Court rebuffed Maryland in its attempt to regulate drug prices, legislative committees are meeting Wednesday on a drug price transparency bill, as well as a bill to create a commission to review prices and set ceilings on insurers, pharmacies and hospitals.
A few weeks after the United States Supreme Court rebuffed Maryland in its attempt to regulate drug prices, legislative committees are meeting Wednesday on a drug price transparency bill, as well as a bill to create a commission to review prices and set ceilings on insurers, pharmacies and hospitals.
The bills have been introduced in both the state Senate and the House of Delegates.
A version of each bill stalled in the legislature last year, The Washington Post reported, because of strong opposition from the pharmaceutical industry. This year, things are different given that the drug industry dropped its opposition since the bill also includes insurers and pharmacy benefit managers.
Maryland had previously attempted to regulate drug prices with a bill that gave Attorney General Brian E. Frosh (D) the ability to sue drug companies if prices rose sharply. But the United States Supreme Court rejected the state’s appeal of a 2018 federal appeals court ruling that struck down the law, which aimed at preventing price-gouging by pharmaceutical companies. The federal ruling held that Maryland had regulated wholesale pricing by the companies in violation of the Constitution's bar on state-level regulation of interstate commerce beyond its borders.
If the bill regarding a pricing commission is signed into law, the resulting 5-person commission would be modeled after the state’s Health Services Cost Review Commission, which sets limits on hospital spending growth, capping what state entities pay.
The body would be an independent unit of government with certain powers, including the ability to review prescription drug costs, request information from manufacturers, and allow the attorney general to pursue “certain remedies.”
For nearly the past 2 months, Congress has been holding hearings on rising drug prices, such as one about skyrocketing insulin costs in the Senate Finance Committee and a House committee hearing that zeroed in on prices for adalimumab (Humira) and Etanercept (Enbrel), both of which have FDA-approved but as-yet unlaunched biosimilars.
And although most focus on drug affordability has been centered on Washington, DC, Maryland not the only state looking to tackle the problem. The National Academy for State Health Policy is tracking bills across the country in the areas of affordability review, price gouging, pharmacy benefit managers, importation, volume purchasing, and more.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.